Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

e-Poster Display session

24P - Evidence for synergy between TNG908, an MTAPnull-selective PRMT5 inhibitor, and sotorasib in an MTAPnull/KRASG12C xenograft model

Date

07 Mar 2022

Session

e-Poster Display session

Presenters

KIMBERLY BRIGGS

Citation

Annals of Oncology (2022) 33 (suppl_1): S9-S12. 10.1016/annonc/annonc839

Authors

K. BRIGGS, G. Corriea, A. Tsai, M. Zhang, M.R. Tonini, E.W. Wilker, C.B. Davis, K.M. Cottrell, J.P. Maxwell, A. Huang

Author affiliations

  • Tango Therapeutics, Inc., Cambridge/US
More

Abstract 24P

Background

MTAP deletion is one of the most common genetic alterations in human cancer, occurring in more than 10% of lung and pancreatic adenocarcinomas. PRMT5 dependence in cells with MTAP deletions is a strong and prevalent synthetic lethal interaction. TNG908 has a novel MTA-cooperative binding mechanism that drives synthetic lethality with MTAP deletion, unlike PRMT5 inhibitors currently in clinical development, and is 15X selective for MTAPnull over MTAPWT cells. Approximately 30% of MTAPnull lung adenocarcinomas and 85% of MTAPnull pancreatic adenocarcinomas are also KRAS-mutant.

Methods

In vitro and in vivo preclinical studies were conducted using cell lines and xenograft models with defined MTAP and KRAS status.

Results

In vitro studies in MTAPnull/KRAS-mutant cancer cell lines demonstrate that combination of MTAPnull-selective PRMT5 inhibitors with MAPK pathway inhibitors, including agents that inhibit ERK, MEK or KRAS, drive a synergistic combination benefit. Approximately 15% of MTAPnull lung adenocarcinomas are also KRASG12C-mutant. In an MTAPnull/KRASG12C-mutant lung adenocarcinoma xenograft model, combination of TNG908 and sotorasib at clinically relevant doses drove tumor regressions, which outperformed exposure-matched single agent activity for either compound, demonstrating a strong in vivo combination benefit.

Conclusions

These data suggest that treatment of KRASG12C-mutant lung adenocarcinoma with TNG908 and a KRASG12C inhibitor may be of clinical benefit in lung cancers with concurrent MTAP deletion and KRASG12C mutation.

Legal entity responsible for the study

Tango Therapeutics.

Funding

Tango Therapeutics.

Disclosure

K. Briggs, A. Tsai, M. Zhang, M.R. Tonini, C.B. Davis, K.M. Cottrell, J.P. Maxwell: Financial Interests, Personal, Full or part-time Employment: Tango Therapeutics; Financial Interests, Personal, Stocks/Shares: Tango Therapeutics. G. Corriea, E.W. Wilker: Financial Interests, Personal, Stocks/Shares: Tango Therapeutics. A. Huang: Financial Interests, Personal, Officer: Tango Therapeutics; Financial Interests, Personal, Full or part-time Employment: Tango Therapeutics; Financial Interests, Personal, Stocks/Shares: Tango Therapeutics.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.